ATE418344T1 - Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten - Google Patents

Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Info

Publication number
ATE418344T1
ATE418344T1 AT01987655T AT01987655T ATE418344T1 AT E418344 T1 ATE418344 T1 AT E418344T1 AT 01987655 T AT01987655 T AT 01987655T AT 01987655 T AT01987655 T AT 01987655T AT E418344 T1 ATE418344 T1 AT E418344T1
Authority
AT
Austria
Prior art keywords
treating diseases
fusion cells
fusion
cytokine compositions
cytokine
Prior art date
Application number
AT01987655T
Other languages
English (en)
Inventor
Tsuneya Ohno
Original Assignee
Tsuneya Ohno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsuneya Ohno filed Critical Tsuneya Ohno
Application granted granted Critical
Publication of ATE418344T1 publication Critical patent/ATE418344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01987655T 2000-10-20 2001-10-22 Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten ATE418344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24215400P 2000-10-20 2000-10-20

Publications (1)

Publication Number Publication Date
ATE418344T1 true ATE418344T1 (de) 2009-01-15

Family

ID=22913659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987655T ATE418344T1 (de) 2000-10-20 2001-10-22 Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Country Status (9)

Country Link
US (2) US20020168351A1 (de)
EP (1) EP1368061B1 (de)
JP (1) JP2004511503A (de)
AT (1) ATE418344T1 (de)
AU (2) AU2002225990B2 (de)
CA (1) CA2426366A1 (de)
DE (1) DE60137146D1 (de)
IL (1) IL155514A0 (de)
WO (1) WO2002032378A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
JP2005534296A (ja) * 2002-05-31 2005-11-17 アポロ ライフ サイエンシズ リミテッド 細胞融合
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
JPWO2005083062A1 (ja) * 2004-02-26 2008-01-17 ジェノミディア株式会社 細胞ワクチン
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
US7225078B2 (en) * 2004-11-03 2007-05-29 Halliburton Energy Services, Inc. Method and system for predicting production of a well
EP2439273B1 (de) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP6069755B2 (ja) 2008-11-24 2017-02-01 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 高親和性ｔ細胞受容体およびその用途
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049803A (en) * 1976-04-26 1977-09-20 Bristol-Myers Company Augmentation of blood levels of aspirin
US20010012632A1 (en) * 1995-03-31 2001-08-09 Muriel Moser Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
ATE388237T1 (de) * 1997-04-15 2008-03-15 Dana Farber Cancer Inst Inc Dendritische zellhybride
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
AU2000236583A1 (en) * 2000-02-27 2001-09-03 Eberhard-Karls-Universitattubingen Universitatsklinikum Hybrid cell vaccines
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer

Also Published As

Publication number Publication date
JP2004511503A (ja) 2004-04-15
AU2002225990B2 (en) 2007-07-19
IL155514A0 (en) 2003-11-23
EP1368061A2 (de) 2003-12-10
WO2002032378A9 (en) 2003-06-26
EP1368061A4 (de) 2005-10-19
EP1368061B1 (de) 2008-12-24
WO2002032378A3 (en) 2003-02-27
CA2426366A1 (en) 2002-04-25
DE60137146D1 (de) 2009-02-05
AU2599002A (en) 2002-04-29
US20020168351A1 (en) 2002-11-14
US20040028663A1 (en) 2004-02-12
WO2002032378A2 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
DE60143857D1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
DE60033649D1 (de) Verbindungen und therapeutische methoden
MY209484A (en) Cpg amphiphiles and uses thereof
TR200001948T2 (tr) Mikobakteri vaccaesinden türetilen kompozisyonlar ve bunların kullanımları için metotlar.
EP1556513A4 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
BR0015597A (pt) Uso de anticorpos como vacinas
EP1037918A4 (de) Verfahren und zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
MXPA03010261A (es) Metodos para tratar cancer.
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
MY127452A (en) Vaccines.
MA27474A1 (fr) Vaccin
DK1537204T3 (da) Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller
DE60044198D1 (de) Aktivierung antigen-spezifischer t-zellen mit virus/antigen-behandelten dendritischen zellen
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties